BioSourcing utilizes a proprietary platform that employs CRISPR-Cas9 gene editing and reproductive technologies to produce monoclonal antibodies in the milk of specially bred goats, significantly lowering production costs and carbon footprint. This approach addresses the global shortage and high costs of biopharmaceuticals, making essential treatments more accessible and sustainable for underserved populations.
Funding
$11.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
EAFounders
Product
Problem
Traditional biopharmaceutical production methods using bioreactors are expensive, require significant capital investment, and have a substantial carbon footprint, limiting the accessibility of essential treatments, especially in emerging economies. The global demand for monoclonal antibodies often exceeds supply, leading to shortages and high costs for patients.
Solution
BioSourcing has developed a proprietary BioMilk platform that leverages CRISPR-Cas9 gene editing and reproductive technologies to produce fully human monoclonal antibodies in the milk of goats. This innovative approach shifts biopharmaceutical production from steel bioreactors to natural bioreactors, significantly reducing capital requirements, production costs, and environmental impact. The resulting biopharmaceuticals, or BioBodies, exhibit improved glycosylation, potentially leading to better efficacy. BioSourcing's platform offers high adaptability and scalability to meet evolving needs, with ease of industrialization and reproducibility.
Target Audience
The primary target audience includes countries, governments, and major industry players seeking more available, affordable, and sustainable biopharmaceutical production methods, as well as pharmaceutical companies looking to reduce production costs and improve the accessibility of essential medicines.
Features
- Proprietary BioMilk platform using CRISPR-Cas9 gene editing to produce biopharmaceuticals in goat milk
- Production of fully human monoclonal antibodies with improved glycosylation
- Drastic reduction of capital requirements and production costs compared to traditional bioreactors
- High adaptability and scalability to meet evolving biopharmaceutical demands
- Ease of industrialization, reproducibility, and relocation of goat farms
- Sustainable production process with a reduced carbon footprint